BIO announces presenting companies for BIO Conference.
Share:
Press Release Summary:
BIO announced initial selection of presenting companies for the 15th Annual BIO CEO & Investor Conference to be held February 11-12, 2013 in New York City. All presenting companies are hand-selected for event, and consist of both private companies and mid-to-large cap established public companies from around the globe. Companies are chosen based on selection process evaluating company’s pipeline and R&D activities as well as their focus on biotechnology therapeutics.
Original Press Release:
BIO Announces Presenting Companies for 15th Annual BIO CEO & Investor Conference
More than 140 Companies Expected to Present Their Story
BIO CEO & Investor Conference 2013:Biotechnology Industry Organization
WASHINGTON -- The Biotechnology Industry Organization (BIO) today announced the initial selection of presenting companies for the 15th Annual BIO CEO & Investor Conference to be held February 11-12, 2013 in New York City. All presenting companies are hand-selected for the event, and consist of both private companies and mid-to-large cap established public companies from around the globe. Companies are chosen based on a selection process evaluating a company’s pipeline and R&D activities as well as their focus on biotechnology therapeutics.
“This year’s conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at our event are publicly traded, with about half trading with market capitalizations above $100M, for the first time this meeting will also include a unique track that features up to 25 high-caliber and established private company presentations,” said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO.
The following companies are slated to present at this year’s conference:
Private Companies:
Actinium Pharmaceuticals
ALS Therapy Development Institute
Aratana Therapeutics
Catabasis Pharmaceuticals
CoLucid Pharmaceuticals
Fate Therapeutics
Five Prime Therapeutics
FORMA Therapeutics
GlobeImmune
Hydra Biosciences
Immune Design Corp
KaloBios Pharmaceuticals
KineMed
Kinex Pharmaceuticals
Leukemia & Lymphoma Society
Mersana
The Michael J. Fox Foundation
Onconova Therapeutics
Polynoma
Promedior
Prosensa Therapeutics
Proteon Therapeutics
Regado Biosciences
Rib-X Pharmaceuticals
Sutro Biopharma
Syndax Pharmaceuticals
Tobira Therapeutics
Trevena
uniQure
Zafgen
Public Companies:
Aastrom Biosciences - ASTM
ACADIA Pharmaceuticals - ACAD
Advanced Cell Technology - ACTC
ADVENTRX Pharmaceuticals - ANX
Affymax - AFFY
Agenus - AGEN
Alkermes - ALKS
Alnylam Pharmaceuticals - ALNY
Anthera Pharmaceuticals - ANTH
Antisense Therapeutics - ASX:ANP
Apricus Biosciences - APRI
Aradigm Corporation - ARDM
Arena Pharmaceuticals - ARNA
Astex Pharmaceuticals - ASTX
Athersys - ATHX
Atossa Genetics - ATOS
Biodel - BIOD
BioDelivery Sciences International - BDSI
BioLineRx - BLRX
BioMarin - BMRN
Biotie Therapies - HEL:BTH1V
Catalyst Pharmaceuticals Partners - CPRX
Celgene Corporation - CELG
CEL-SCI Corporation - CVM
Cempra - CEMP
ChemoCentryx - CCXI
Cleveland BioLabs - CBLI
Curis - CRIS
Cyclacel Pharmaceuticals - CYCC
Cytokinetics - CYTK
CytRx Corporation - CYTR
DARA BioSciences - DARA
DiaMedica - CVE:DMA
DURECT Corporation - DRRX
Eli Lilly - LLY
EpiCept Corporation - EPCT
Eternity Healthcare - ETAH
Exelixis - EXEL
Furiex Pharmaceuticals - FURX
Galena BioPharma - GALE
GENFIT - EPA:ALGFT
GenVec - GNVC
GeoVax Labs - GOVX
Gilead Sciences - GILD
GTx - GTXI
Horizon Pharma - HZNP
Hyperion Therapeutics - HPTX
iCo Therapeutics - CVE:ICO
Idenix Pharmaceuticals - IDIX
Idera Pharmaceuticals - IDRA
ImmunoCellular Therapeutics - IMUC
ImmunoGen - IMGN
Immunovaccine - CVE:IMV
Inovio Pharmaceuticals - INO
Intercept Pharmaceuticals - ICPT
Lexicon Pharmaceuticals - LXRX
MDx Health - EBR:MDXH
NanoViricides - NNVC
Navidea - NAVB
NeoStem - NBS
Neuralstem - CUR
Newron Pharmaceuticals - NWRN-CH
NicOx - EPA:COX
NovaBay Pharmaceuticals - NBY
Novavax - NVAX
Novelos Therapeutics - NVLT
NPS Pharmaceuticals - NPSP
Nymox Pharmaceutical Corporation - NYMX
Oculus Innovative Sciences - OCLS
Ohr Pharmaceutical - OHRP
OncoGenex Pharmaceuticals - OGXI
Oncolytics Biotech - TSE:ONC
OncoSec Medical - ONCS
Onyx Pharmaceuticals - ONXX
Opexa Therapeutics - OPXA
Oragenics - OGEN
Orexigen - OREX
OXiGENE - OXGN
Palatin Technologies - PTN
PDL BioPharma - PDLI
Pozen - POZN
Prima Biomed - ASX:PRR
ProMetic Life Sciences - TSE:PLI
Protalix BioTherapeutics - PLX
Provectus Pharmaceuticals - PVCT
pSiVida Corp - PSDV
Q Therapeutics
Regulus Therapeutics - RGLS
ReNeuron - LON:RENE
Repros Therapeutics - RPRX
Resverlogix - TSE:RVX
Rigel Pharmaceuticals - RIGL
RXi Pharmaceuticals - RXII
SciClone Pharmaceuticals - SCLN
Soligenix - SNGX
Stallergenes - EPA:GENP
StemCells - STEM
Sucampo Pharmaceuticals - SCMP
Synthetic Biologics - SYN
Targacept - TRGT
Tekmira Pharmaceuticals Corp - TSE:TKM
Tengion - TNGN
TG Therapeutics - TGTX
TiGenix - EBR:TIG
Tonix Pharmaceuticals - TNXP
Transcept Pharmaceuticals - TSPT
Transition Therapeutics - TSE:TTH
Tranzyme - TZYM
TrovaGene - TROV
Venaxis - APPY
Verastem - VSTM
VirtualScopics - VSCP
Zalicus - ZLCS
Zealand Pharma - ZEAL
ZIOPHARM Oncology - ZIOP
Check back often as new presenters are continuously being added. Companies interested in presenting their story can submit an application at www.bio.org/events/conferences/bio-ceo-application-present.
About BIO CEO & Investor Conference
The BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The BIO CEO & Investor Conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks Stifel Nicolaus Weisel, Leerink Swann and ROTH Capital Partners, LLC.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
Upcoming BIO Events
BIO Asia International Conference
January 29 - 30, 2013
Tokyo, Japan
BIO CEO & Investor Conference
February 11 - 12, 2013
New York City, NY
BIO IPCC Conference
March 25 - 27, 2013
San Diego, CA
BIO International Convention
April 22 - 25, 2013
Chicago, IL
World Congress on Industrial Biotechnology
June 16 - 19, 2013
Montreal, Canada
Contacts
Biotechnology Industry Organization (BIO)
Abigail Hirsch, 1-202-962-9235
ahirsch@bio.org
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
